JP Morgan Put 410 VRTX 16.01.2026/ DE000JK7LUN9 /
2024-05-30 8:33:22 AM | Chg.+0.26 | Bid1:39:16 PM | Ask1:39:16 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
4.51EUR | +6.12% | 4.43 Bid Size: 1,000 |
4.93 Ask Size: 1,000 |
Vertex Pharmaceutica... | 410.00 USD | 2026-01-16 | Put |
GlobeNewswire
05-15
Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
05-09
CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference
GlobeNewswire
05-08
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
GlobeNewswire
05-08
CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo ...
GlobeNewswire
05-07
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
04-30
American Kidney Fund Encourages People to Be APOL1 Aware with First Annual APOL1-Mediated Kidney Dis...
GlobeNewswire
04-27
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLC Investigates MODN, AIRC, INRD, ALPN
GlobeNewswire
04-22
TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - ALPN, LABP, SWAV, FUS...
GlobeNewswire
04-22
CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASG...
GlobeNewswire
04-09
American Kidney Fund and Alonzo Mourning Call for More Awareness and Understanding of APOL1-Mediated...
GlobeNewswire
04-03
CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference
GlobeNewswire
04-01
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
GlobeNewswire
04-01
CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Me...
GlobeNewswire
03-15
American Kidney Fund Announces 2024 Class of Corporate Members Providing Support in the Fight Agains...
GlobeNewswire
03-13
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results